Substitutions in the reverse transcriptase and protease genes of HIV-1 subtype B in untreated individuals and patients treated with antiretroviral drugs

MedGenMed Medscape General Medicine

Volumn 7, Issue 1, 2005, Pages

  Turner, Dan ^a   Brenner, Bluma ^a   Moisi, Daniela ^a   Liang, Chen ^a   Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FREQUENCY ANALYSIS; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; PREVALENCE; SEQUENCE ANALYSIS; SUBSTITUTION REACTION; VIRUS LOAD;

EID: 25144451296     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: 10.1186/1758-2652-7-1-69     Document Type: Article

References (28)

1. Preston BD, Dougherty JP. Mechanisms of retroviral mutation. Trends Microbiol. 1996;4:16-21.
2. Quinones-Mateu M, Weber J, Rangel H, Charkaborty B. HIV-1 fitness and antiretroviral drug resistance. AIDS Rev. 2001;3:223-242.
3. Rezende LF, Drosopoulos WC, Prasad VR. The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase. Nucleic Acids Res. 1998;26:3066-3072.
4. Roberts J, Bebenek K, Kunkel T. The accuracy of reverse transcriptase from HIV-1. Science. 1998;242:1171-1173.
5. Harris RS, Bishop KN, Sheehy AM, et al. DNA deamination mediates innate immunity to retroviral infection. Cell. 2003;113:803-809.
6. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science. 2003;300:1112.
7. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003;424:99-103.
8. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003;424:94-98.
9. Salomon H, Wainberg M-A, Brenner B, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS. 2000;14:F17-F23.
10. Ross L, Fisher R, Scaesella A. Patients failing on stavudine-based therapies that have developed thymidine analogue mutations; multidrug resistance or V75T mutations have reduced phenotypic susceptibility to stadivudine. Antiviral Therapy. 2000;5:38-39.
11. Borman AM, Quillent C, Charneau P, Kean KM, Clavel F. A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G-->A hypermutation during negative-strand viral DNA synthesis. Virology. 1995;208:601-609.
12. Delassus S, Cheynier R, Wain-Hobson S. Evolution of human immunodeficiency virus type 1 nef and long terminal repeat sequences over 4 years in vivo and in vitro. J Virol. 1991;65, 225-231.
13. Fitzgibbon JE, Mazar S, Dubin DT. A new type of G-->A hypermutation affecting human immunodeficiency virus. AIDS Res Hum Retroviruses. 1993;9:833-838.
14. Goodenow M, Huet T, Saurin W, et al. HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr. 1989;2:344-352.
15. Janini M, Rogers M, Birx DR, McCutchan FE. Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J Virol. 2001;75:7973-7986.
16. Liu Y, Tang XP, McArthur JC, Scott J, Gartner S. Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neurovirol. 2000;6(suppl 1):S70-S81.
17. Monken CE, Wu B, Srinivasan A. High resolution analysis of HIV-1 quasispecies in the brain. AIDS. 1995;9:345-349.
18. Vartanian JP, Meyerhans A, Asjo B, Wain-Hobson S. Selection, recombination, and G→→A hypermutation of human immunodeficiency virus type 1 genomes. J Virol. 1991;65:1779-1788.
19. Yoshimura FK, Diem K, Learn GH, Riddell S Jr, Corey L. Intrapatient sequence variation of the gag gene of human immunodeficiency virus type 1 plasma virions. J Virol. 1996;70:8879-8887.
20. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS. 2003;17, F1-F5.
21. Keulen W, Back NK, van Wijk A, Boucher CA, Berkhout B. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol. 1997;71:3346-3350.
22. Keulen W, Boucher C, Berkhout B. Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. Antiviral Res. 1996;31:45-57.
23. Caride E, Brindeiro RM, Kallas EG, et al. Sexual transmission of HIV-1 isolate showing G-->A hypermutation. J Clin Virol. 2002;23,179-189.
24. Meyerhans A, Vartanian JP, Hultgren C, et al. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol. 1994;68:535-540.
25. Martinez MA, Vartanian JP, Wain-Hobson S. Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc Natl Acad Sci U S A. 1994;91:11787-11791.
26. Vartanian JP, Meyerhans A, Sala M, Wain-Hobson S. G-->A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci U S A. 1994;91:3092-3096.
27. Balzarini J, Camarasa MJ, Perez-Perez MJ, et al. Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV. J Virol. 2001;75:5772-5777.
28. Trono D. Innate intracellular antiretroviral defences. Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract 121.